GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Tvardi Therapeutics Inc (LTS:0HTC) » Definitions » Net Income Including Noncontrolling Interests

Tvardi Therapeutics (LTS:0HTC) Net Income Including Noncontrolling Interests : £-3.80 Mil (TTM As of Mar. 2025)


View and export this data going back to 2025. Start your Free Trial

What is Tvardi Therapeutics Net Income Including Noncontrolling Interests?

Net Income Including Noncontrolling Interests is the net income of the group after the adjustment of all expenses and benefit. It includes the net income (loss) attributable to noncontrolling and redeemable noncontrolling interests and the net income (loss) attributable to the company.

Tvardi Therapeutics's Net Income Including Noncontrolling Interests for the three months ended in Mar. 2025 was £-3.80 Mil. Its Net Income Including Noncontrolling Interests for the trailing twelve months (TTM) ended in Mar. 2025 was £-3.80 Mil.

Tvardi Therapeutics Net Income Including Noncontrolling Interests Historical Data

The historical data trend for Tvardi Therapeutics's Net Income Including Noncontrolling Interests can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tvardi Therapeutics Net Income Including Noncontrolling Interests Chart

Tvardi Therapeutics Annual Data
Trend Dec22 Dec23
Net Income Including Noncontrolling Interests
-16.87 -13.70

Tvardi Therapeutics Quarterly Data
Dec22 Dec23 Mar24 Sep24 Mar25
Net Income Including Noncontrolling Interests - -3.44 -24.16 - -3.80

Tvardi Therapeutics Net Income Including Noncontrolling Interests Calculation

Net Income Including Noncontrolling Interests is the net income of the group after the adjustment of all expenses and benefit. It includes the net income (loss) attributable to noncontrolling and redeemable noncontrolling interests and the net income (loss) attributable to the company.

Net Income Including Noncontrolling Interests for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was £-3.80 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Tvardi Therapeutics Net Income Including Noncontrolling Interests Related Terms

Thank you for viewing the detailed overview of Tvardi Therapeutics's Net Income Including Noncontrolling Interests provided by GuruFocus.com. Please click on the following links to see related term pages.

Tvardi Therapeutics Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Tvardi Therapeutics Inc (LTS:0HTC) » Definitions » Net Income Including Noncontrolling Interests
Comparable Companies
CADL GOSS OCGN CRVS TSVT ALMS PHAT TERN HRTX PVLA VRTX ASX:CSL REGN XKRX:207940 ALNY XBRU:ARGX XBRU:UCB ONC XKRX:068270 BNTX
Traded in Other Exchanges
TVRD:USA 69C:Germany
Address
3 Sugar Creek Center boulevard, Suite 525, Sugar Land, TX, USA, 77478
Website
Tvardi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development of novel, oral small molecule therapies targeting STAT3 to treat fibrosis-driven diseases. Its key product candidate, TTI-101, is in Phase 2 clinical development for the treatment of idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC). Its second product candidate, TTI-109, is structurally related to, yet chemically distinct from, TTI-101 and is designed to enhance the ability to target STAT3.

Tvardi Therapeutics Headlines

No Headlines